Compatible Effect of Remimazolam Besylate Combined With Afentanil for ATI
NCT ID: NCT06026566
Last Updated: 2023-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
180 participants
INTERVENTIONAL
2023-04-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. To determine the optimal dosage of the two drugs in awake endotracheal intubation;
3. To provide clinical guidance for awake endotracheal intubation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Study of Continuous Infusion of Remazolam in Mechanically Ventilated Patients in ICU
NCT05480787
Comparison of Remifentanil with a Combination of Remimazolam and Dexmedetomidine for Awake Tracheal Intubation
NCT06581731
Pharmacodynamic Interactions of Propofol and Dexmedetomidine on Intravenous Anesthesia
NCT02777619
Dexmedetomidine Versus Propofol for Sedation During Awake Endotracheal Intubation
NCT04753515
The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.
NCT07335536
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ATI refers to tracheal intubation while the patient is awake and breathing spontaneously, most commonly by flexible bronchoscopy (FB) or video laryngoscopy (VL), which allows for airway control prior to induction of general anesthesia. Thus, the potential risks and consequences of difficulty in establishing the airway after anesthesia induction are avoided. The safety of ATI is reflected in the guarantee of spontaneous breathing and intrinsic airway tension of patients before tracheal tube insertion. The failure rate of ATI is only 1-2%, and it rarely requires airway first aid or causes patient death.
ATI is currently the safest technique for dealing with difficult airways, but it accounts for only 0.2% of all tracheal intubation types in the UK. The reason is that ATI operators may be under great physical, mental, and psychological stress, which may lead to poor performance and increase the risk of complications, including failure. In addition, mechanical stimulation of the airway in the awake state can cause coughing, nausea, restlessness and other reactions to tracheal intubation, resulting in adverse consequences. Therefore, before the effective implementation of ATI, anesthesiologists often choose to combine small doses of analgesic and sedative drugs to achieve the minimum degree of sedation effect, so as to reduce the anxiety and discomfort of patients and improve the tolerance of patients.
Studies have shown that drugs such as fentanyl, remifentanil, midazolam, propofol and dexmedetomidine can be used to assist ATI to improve patient satisfaction and reduce the risk of excessive sedation and airway obstruction. However, these drugs have different degrees of cardiovascular or respiratory adverse reactions, especially when used in large doses, which increases the risk of hypoxemia, hypotension or bradycardia. ATI guidelines suggest that excessive sedation is very dangerous for some patients, and it is recommended to use it with caution, and a minimum degree of reversible sedation is preferred. Therefore, how to ensure good sedation and analgesia and maintain normal spontaneous breathing is worthy of further study.
Remimazolam besylate is a new type of benzodiazepine, which is an ultra-short-acting sedative/anesthetic drug. The mechanism is that by binding to benzodiazepine receptors, it specifically acts on GABAA receptors, enhances GABAA receptor activity, and selectively promotes extracellular chloride ions into cells, leading to hyperpolarization of cell membrane resting potential and decreased excitability, thus inhibiting neuronal electrical activity and producing sedative effect. And this effect can be specifically antagonized by flumazenil. As an important member of opioid receptor agonist, 30s of alfentanil exerts its drug effect, and its safety is far better than that of morphine. Alfentanil does not cause severe respiratory depression in the therapeutic dose range, and can reduce the use of sedative drugs when used in combination. In gastrointestinal endoscopy, hysteroscopy, fiberoptic bronchoscopy and other procedures with spontaneous breathing, alfentanil alone or in combination with benzodiazepines shows mild respiratory depression and high safety.
The purpose of this study is to study the pharmacokinetics between remimazolam besylate and alfentanil hydrochloride by response surface analysis, to determine the standard drug concentration under spontaneous breathing, and to observe the clinical effect of awake tracheal intubation under this concentration dose, to explore the best compatible dose range of the two drugs, in order to provide a reference for clinical application in patients with difficult airway.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dos of R 0.1
The dosage of Remimazolam Besylate is 0.1 mg/kg
Dos of Afentanil 50
the dosage of Afentanil is 50 ng/ml for TCI
Dos of Afentanil 60
the dosage of Afentanil is 60 ng/ml for TCI
Dos of Afentanil 70
the dosage of Afentanil is 70 ng/ml for TCI
Dos of Afentanil 80
the dosage of Afentanil is 80 ng/ml for TCI
Dos of Afentanil 90
the dosage of Afentanil is 90 ng/ml for TCI
Dos of Afentanil 100
the dosage of Afentanil is 100 ng/ml for TCI
Dos of R 0.15
The dosage of Remimazolam Besylate is 0.15 mg/kg
Dos of Afentanil 40
the dosage of Afentanil is 40 ng/ml for TCI
Dos of Afentanil 50
the dosage of Afentanil is 50 ng/ml for TCI
Dos of Afentanil 60
the dosage of Afentanil is 60 ng/ml for TCI
Dos of Afentanil 70
the dosage of Afentanil is 70 ng/ml for TCI
Dos of Afentanil 80
the dosage of Afentanil is 80 ng/ml for TCI
Dos of Afentanil 90
the dosage of Afentanil is 90 ng/ml for TCI
Dos of R 0.2
The dosage of Remimazolam Besylate is 0.2 mg/kg
Dos of Afentanil 30
the dosage of Afentanil is 30 ng/ml for TCI
Dos of Afentanil 40
the dosage of Afentanil is 40 ng/ml for TCI
Dos of Afentanil 50
the dosage of Afentanil is 50 ng/ml for TCI
Dos of Afentanil 60
the dosage of Afentanil is 60 ng/ml for TCI
Dos of Afentanil 70
the dosage of Afentanil is 70 ng/ml for TCI
Dos of Afentanil 80
the dosage of Afentanil is 80 ng/ml for TCI
Dos of R 0.25
The dosage of Remimazolam Besylate is 0.25 mg/kg
Dos of Afentanil 30
the dosage of Afentanil is 30 ng/ml for TCI
Dos of Afentanil 40
the dosage of Afentanil is 40 ng/ml for TCI
Dos of Afentanil 50
the dosage of Afentanil is 50 ng/ml for TCI
Dos of Afentanil 60
the dosage of Afentanil is 60 ng/ml for TCI
Dos of Afentanil 70
the dosage of Afentanil is 70 ng/ml for TCI
Dos of Afentanil 80
the dosage of Afentanil is 80 ng/ml for TCI
Dos of R 0.3
The dosage of Remimazolam Besylate is 0.3 mg/kg
Dos of Afentanil 20
the dosage of Afentanil is 20 ng/ml for TCI
Dos of Afentanil 30
the dosage of Afentanil is 30 ng/ml for TCI
Dos of Afentanil 40
the dosage of Afentanil is 40 ng/ml for TCI
Dos of Afentanil 50
the dosage of Afentanil is 50 ng/ml for TCI
Dos of Afentanil 60
the dosage of Afentanil is 60 ng/ml for TCI
Dos of Afentanil 70
the dosage of Afentanil is 70 ng/ml for TCI
Dos of R 0.35
The dosage of Remimazolam Besylate is 0.25 mg/kg
Dos of Afentanil 20
the dosage of Afentanil is 20 ng/ml for TCI
Dos of Afentanil 30
the dosage of Afentanil is 30 ng/ml for TCI
Dos of Afentanil 40
the dosage of Afentanil is 40 ng/ml for TCI
Dos of Afentanil 50
the dosage of Afentanil is 50 ng/ml for TCI
Dos of Afentanil 60
the dosage of Afentanil is 60 ng/ml for TCI
Dos of Afentanil 70
the dosage of Afentanil is 70 ng/ml for TCI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dos of Afentanil 20
the dosage of Afentanil is 20 ng/ml for TCI
Dos of Afentanil 30
the dosage of Afentanil is 30 ng/ml for TCI
Dos of Afentanil 40
the dosage of Afentanil is 40 ng/ml for TCI
Dos of Afentanil 50
the dosage of Afentanil is 50 ng/ml for TCI
Dos of Afentanil 60
the dosage of Afentanil is 60 ng/ml for TCI
Dos of Afentanil 70
the dosage of Afentanil is 70 ng/ml for TCI
Dos of Afentanil 80
the dosage of Afentanil is 80 ng/ml for TCI
Dos of Afentanil 90
the dosage of Afentanil is 90 ng/ml for TCI
Dos of Afentanil 100
the dosage of Afentanil is 100 ng/ml for TCI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. deviation from ideal body weight ≤25%;
\[Ideal weight (kg) = height (cm) -100 (male) or 105 (female)\]
3. American Society of Anesthesiologists grade Ⅰ-II;
4. Informed consent: voluntarily participate in the trial and sign the informed consent.
Exclusion Criteria
2. Relative contraindications: patients with respiratory diseases, allergy to local anesthetics, airway bleeding, and non-cooperation;
3. patients known to be allergic to remimazolam besylate or benzodiazepines;
4. patients with known allergy to alfentanil or opioids;
5. body weight exceeding ±25% of ideal body weight;
6. patients with coagulation dysfunction, endocrine diseases or other hemodynamic conditions;
7. patients with a history of drug or alcohol dependence;
8. Subjects who were deemed unsuitable for the study by the investigators.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tongji Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qiaoqiao Xu
Associate professor and deputy chief physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qiaoqiao Xu
Role: PRINCIPAL_INVESTIGATOR
Tongji Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital, Tongji Medical College, Huazhong Science and Technology University
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Bi SS, Deng CH, Zhou TY, Guan Z, Li L, Li HQ, Zhang LP, Yang L, Lu W. Remifentanil-sevoflurane interaction models of circulatory response to laryngoscopy and circulatory depression. Br J Anaesth. 2013 May;110(5):729-40. doi: 10.1093/bja/aes504. Epub 2013 Feb 6.
Ahmad I, El-Boghdadly K, Bhagrath R, Hodzovic I, McNarry AF, Mir F, O'Sullivan EP, Patel A, Stacey M, Vaughan D. Difficult Airway Society guidelines for awake tracheal intubation (ATI) in adults. Anaesthesia. 2020 Apr;75(4):509-528. doi: 10.1111/anae.14904. Epub 2019 Nov 14.
Ajay S, Singhania A, Akkara AG, Shah A, Adalja M. A study of flexible fiberoptic bronchoscopy aided tracheal intubation for patients undergoing elective surgery under general anesthesia. Indian J Otolaryngol Head Neck Surg. 2013 Apr;65(2):116-9. doi: 10.1007/s12070-012-0576-8. Epub 2012 Oct 17.
Cook TM. Strategies for the prevention of airway complications - a narrative review. Anaesthesia. 2018 Jan;73(1):93-111. doi: 10.1111/anae.14123.
El-Boghdadly K, Onwochei DN, Cuddihy J, Ahmad I. A prospective cohort study of awake fibreoptic intubation practice at a tertiary centre. Anaesthesia. 2017 Jun;72(6):694-703. doi: 10.1111/anae.13844.
Joseph TT, Gal JS, DeMaria S Jr, Lin HM, Levine AI, Hyman JB. A Retrospective Study of Success, Failure, and Time Needed to Perform Awake Intubation. Anesthesiology. 2016 Jul;125(1):105-14. doi: 10.1097/ALN.0000000000001140.
Law JA, Morris IR, Brousseau PA, de la Ronde S, Milne AD. The incidence, success rate, and complications of awake tracheal intubation in 1,554 patients over 12 years: an historical cohort study. Can J Anaesth. 2015 Jul;62(7):736-44. doi: 10.1007/s12630-015-0387-y. Epub 2015 Apr 24.
Alhomary M, Ramadan E, Curran E, Walsh SR. Videolaryngoscopy vs. fibreoptic bronchoscopy for awake tracheal intubation: a systematic review and meta-analysis. Anaesthesia. 2018 Sep;73(9):1151-1161. doi: 10.1111/anae.14299. Epub 2018 Apr 17.
Cook TM, Woodall N, Frerk C; Fourth National Audit Project. Major complications of airway management in the UK: results of the Fourth National Audit Project of the Royal College of Anaesthetists and the Difficult Airway Society. Part 1: anaesthesia. Br J Anaesth. 2011 May;106(5):617-31. doi: 10.1093/bja/aer058. Epub 2011 Mar 29.
Weinger MB, Vredenburgh AG, Schumann CM, Macario A, Williams KJ, Kalsher MJ, Smith B, Truong PC, Kim A. Quantitative description of the workload associated with airway management procedures. J Clin Anesth. 2000 Jun;12(4):273-82. doi: 10.1016/s0952-8180(00)00152-5.
Johnston KD, Rai MR. Conscious sedation for awake fibreoptic intubation: a review of the literature. Can J Anaesth. 2013 Jun;60(6):584-99. doi: 10.1007/s12630-013-9915-9. Epub 2013 Mar 20.
He XY, Cao JP, He Q, Shi XY. Dexmedetomidine for the management of awake fibreoptic intubation. Cochrane Database Syst Rev. 2014 Jan 19;2014(1):CD009798. doi: 10.1002/14651858.CD009798.pub2.
Moller IW, Krantz T, Wandall E, Kehlet H. Effect of alfentanil anaesthesia on the adrenocortical and hyperglycaemic response to abdominal surgery. Br J Anaesth. 1985 Jun;57(6):591-4. doi: 10.1093/bja/57.6.591.
Lin YJ, Wang YC, Huang HH, Huang CH, Liao MX, Lin PL. Target-controlled propofol infusion with or without bispectral index monitoring of sedation during advanced gastrointestinal endoscopy. J Gastroenterol Hepatol. 2020 Jul;35(7):1189-1195. doi: 10.1111/jgh.14943. Epub 2019 Dec 6.
Chiang MH, Wu SC, You CH, Wu KL, Chiu YC, Ma CW, Kao CW, Lin KC, Chen KH, Wang PC, Chou AK. Target-controlled infusion vs. manually controlled infusion of propofol with alfentanil for bidirectional endoscopy: a randomized controlled trial. Endoscopy. 2013 Nov;45(11):907-14. doi: 10.1055/s-0033-1344645. Epub 2013 Oct 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TongjiHospital-Anes QQ01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.